ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $192,691,423 | -22.7% | 5,405,089 | 0.0% | 4.07% | -14.3% |
| Q2 2023 | $249,336,756 | +45.6% | 5,405,089 | +26.6% | 4.75% | +33.1% |
| Q1 2023 | $171,266,940 | -6.8% | 4,270,996 | +7.7% | 3.57% | -5.0% |
| Q4 2022 | $183,787,172 | +88.1% | 3,966,915 | +68.1% | 3.75% | +66.5% |
| Q3 2022 | $97,727,000 | +19.3% | 2,359,996 | +71.9% | 2.25% | +6.4% |
| Q2 2022 | $81,930,000 | -17.8% | 1,373,284 | 0.0% | 2.12% | +2.6% |
| Q1 2022 | $99,728,000 | -13.6% | 1,373,284 | 0.0% | 2.06% | +22.4% |
| Q4 2021 | $115,479,000 | – | 1,373,284 | – | 1.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |